Filtered By:
Management: Medicaid
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 545 results found since Jan 2013.
Reducing Cancer Care Costs and Hospital Stays
There are two really irritating things about cancer care for me. (Well there are really lots of things that irritate me about cancer care. I could make a giant list of them if anyone really cared but today I am going to focus on two things.Cancer care is ridiculously expensive. You can take a drug for $100,000 that might increase your lifespan for a couple of months. A single chemo infusion can cost upwards of $20,000.And at the least sign of germs or low blood counts, you are sent to the emergency room where they admit you. That is a really stupid part. You feel like crap on a Friday night, you call your oncologist and th...
Source: Caroline's Breast Cancer Blog - November 13, 2016 Category: Cancer & Oncology Tags: cancer care cancer costs hospital Source Type: blogs
Dear (Quite Possibly) President Trump
By MARGALIT GUR-ARIE
Even the most ardent of Obamacare supporters are now forced to admit that the law has hit a rough patch this year. The opposition to Obamacare is positively gloating with self-congratulatory “I told you so” assessments of the supposedly dire situation. Defenders of the cause are counteracting with the customary deluge of charts and graphs to prove unequivocally that Obamacare is actually turning out better than they expected. Integrity and honesty being in short supply on both sides of this quandary, chances are excellent that no matter what happens next, the American people will lose big time, unl...
Source: The Health Care Blog - November 3, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized election 2016 Trump Source Type: blogs
The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs
Two years ago, soon after the Food & Drug Administration (FDA) approved the first breakthrough treatment for hepatitis C, we wrote about the potential cost of a cure to Medicare Part D and its beneficiaries. For that piece, we used the best available data to estimate the number of people on Medicare who might seek treatment and the impact on Medicare spending. Here we revisit our earlier analysis using new data released by CMS, and consider both the ongoing impact of hepatitis C drugs for Part D and the broader implications for Medicare of new high-priced drugs entering the market.
Hepatitis C Drugs Have Driven Drug Sp...
Source: Health Affairs Blog - November 3, 2016 Category: Health Management Authors: Jack Hoadley, Tricia Neuman and Juliette Cubanski Tags: Drugs and Medical Innovation Medicare FDA Harvoni hepatitis C prescription drug prices Sovaldi Source Type: blogs
CMS Issues Final Rule on CY 2017 Physician Fee Schedule
Conclusion
The CY 2017 PFS final rule is the latest showing of the Administration-wide strategy to create a health care system that results in better care, smarter spending, and a healthier population.
Related StoriesOpen Payments Having an Adverse Effect on Physician-Rep RelationshipsCMS Bundled Payments for Care Improvement Evaluation ReleasedCMS Releases MA and Part D Landscape Information for 2017
Source: Policy and Medicine - November 2, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
The Perversion of Fiscal Federalism: Daniel L. Hatcher ’ s, “ The Poverty Industry: The Exploitation of America ’ s Most Vulnerable Citizens ”
By DAVID INTROCASO
It’s not that we do not know that Medicaid and Medicare fraud is rampant. A 2012 estimate by the former CMS administrator, Donald Berwick, estimated the amount at $100 billion annually. Nor are we unaware, that drug companies routinely pay massive fines for illegal business practices: eight firms have paid in sum over $11.2 billion in civil and criminal fines since 2010. Beyond these issues what is possibly most disturbing about the numerous inter-related health and human services issues “The Poverty Industry” raises is Professor Hatcher’s detailed discussion of how state human ser...
Source: The Health Care Blog - November 1, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs
Encouraging Integrative, Non-opioid Approaches To Pain: A Policy Agenda
The United States is struggling to deal with an opioid epidemic that is damaging lives, resulting in overdoses, and yet not reducing chronic pain. National initiatives are underway to dramatically reduce access to prescription opioids, but these efforts lack a systematic approach to provide alternative treatments for these patients. Policy changes are urgently needed to provide better care for patients with chronic pain, and in this post, we outline three feasible policy initiatives.
Innovative reimbursement initiatives by the Centers for Medicare and Medicaid Services (CMS) could frame and stimulate use of evidence-based ...
Source: Health Affairs Blog - October 4, 2016 Category: Health Management Authors: Jason Doctor, Penny Cowan, Daniella Meeker, Patricia Bruckenthal and Joan Broderick Tags: Drugs and Medical Technology Health Professionals Public Health Quality chronic pain Opioid Addiction opioids Source Type: blogs
ACA Round-Up: Appropriations, Battles Over Reinsurance Program Collections, And More
On September 29, President Obama signed a continuing resolution appropriations bill that will fund the government through December 9, 2016, unless a 2017 appropriations bill is passed before that date. The headline is that the bill provides $1.1 billion in funding for combating the Zika virus. But the legislation otherwise continues in place funding for ACA programs at the rates at which they were funded for 2016, subject to a half percent reduction.
The continuing resolution retains riders and restrictions imposed by the 2016 appropriations legislation, including restrictions on using HHS administrative funds to fund the ...
Source: Health Affairs Blog - September 30, 2016 Category: Health Management Authors: Timothy Jost Tags: Following the ACA Insurance and Coverage ACA litigation appropriations ASPE GAO reinsurance program Zika virus Source Type: blogs
Fail to Scale: Why Great Ideas In Healthcare Don ’ t Thrive Everywhere
By JEFF GOLDSMITH and LAWTON BURNS
In the world of fine wine, it is well known that some types of wine grapes grow only in very specific climates and ecologies. The concept borrowed from the French is “terroir” (ter-WAHR). Terroir explains why the finest champagne grapes grow only in a small district in northeastern France, characterized by rolling hills and a chalky limestone subsoil that provides a steady level of moisture and imparts a mineral note to the wine’s flavor.
Health policy advocates have sought for generations to propagate promising forms of health care organization across the country. Yet one finds rep...
Source: The Health Care Blog - September 29, 2016 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs
Fail To Scale: Why Great Ideas In Health Care Don ’t Thrive Everywhere
In the world of fine wine, it is well known that some types of wine grapes grow only in very specific climates and ecologies. The concept borrowed from the French is “terroir” (ter-WAHR). Terroir explains why the finest champagne grapes grow only in a small district in northeastern France, characterized by rolling hills and a chalky limestone subsoil that provides a steady level of moisture and imparts a mineral note to the wine’s flavor.
Health policy advocates have sought for generations to propagate promising forms of health care organization across the country. Yet one finds repeatedly that some forms of organiza...
Source: Health Affairs Blog - September 29, 2016 Category: Health Management Authors: Jeff Goldsmith and Lawton Burns Tags: Costs and Spending Featured Insurance and Coverage Medicare Payment Policy Independent Practice Association Medicare fraud States Source Type: blogs
How To Think About Health Technology Assessment: A Response To Goldman And Coauthors
From 3,000 miles away—on the other side of the Atlantic and more precisely from England—it is hard not to sense a note of frustration in the Health Affairs Blog post by Dana Goldman, Sam Nussbaum, and Mark Linthicum: “We need health technology assessment. Only we can’t have it. Because we are us. But we need it. But we can’t have it. So what do we do?”
It is also hard not to offer sympathy, not least because every country that has what the three authors dub “full” health technology assessment (also referred to here as “HTA”) finds it endlessly controversial. But at least some of the dilemma that...
Source: Health Affairs Blog - September 15, 2016 Category: Health Management Authors: Nicholas Timmins Tags: Costs and Spending Drugs and Medical Innovation Featured Health IT Europe health technology assessment National Health Service Source Type: blogs
Rapid Biomedical Innovation Calls For Similar Innovation In Pricing And Value Measurement
Advances in foundational science, technology, and clinical knowledge are driving a revolution in patient care. Minimally invasive surgery has reduced rates of post-surgical complications, reduced hospitalization, and dramatically accelerated recovery; direct-acting antivirals have brought a cure for hepatitis C; and novel immunotherapies have brought the promise of increased survival to late-stage cancer patients. The list goes on.
At the same time, spending on these innovative drugs and devices has increased dramatically. Between 1980 and 2010, overall personal health care expenditures in the US grew nearly four-fold, dri...
Source: Health Affairs Blog - September 15, 2016 Category: Health Management Authors: Dana Goldman, Samuel Nussbaum and Mark Linthicum Tags: Drugs and Medical Innovation Featured Comparative Effectiveness health technology assessment National Health Service National Institute for Health and Care Excellence PCORI Source Type: blogs
Medi-Cal for all: It ’s coming soon
The Affordable Care Act has been touted as the answer to our country’s huge uninsured epidemic. There is no denying the fact that millions of uninsured people signed up for insurance through an expanded Medicaid program, which is called Medi-Cal in California. The blessings of a decrease in uninsured patients makes for a great sound bite and has been repeated over and over in the media. The only problem is that Medi-Cal is a lousy excuse for insurance and in my opinion should not be allowed to be called insurance at all. Its existence as an insurance option endangers the whole insurance industry.
First of all, let’s no...
Source: Kevin, M.D. - Medical Weblog - September 11, 2016 Category: Journals (General) Authors: < a href="http://www.kevinmd.com/blog/post-author/manuel-momjian" rel="tag" > Manuel Momjian, MD < /a > Tags: Physician Primary care Source Type: blogs
Call for Papers: End of Life Ethics in Oncology Practice Special Series
The Journal of Oncology Practice (JOP) is now accepting manuscripts to become part of a thematic issue on “End of Life (EOL) Care and Ethics” in adult and pediatric oncology.
Original work including original research papers (of up to 3,000 words), commentaries, narratives, point/counterpoint companion pieces on controversial topics (of 1,500-1,800) will be considered in all areas of oncology practice.
Suggested topics include: •Collaboration between oncologists, intensivists, and other specialties caring for cancer patients in the ICU •Use of multidisciplinary teams and models for best pr...
Source: blog.bioethics.net - September 11, 2016 Category: Medical Ethics Authors: Thaddeus Mason Pope, JD, PhD Tags: Health Care medical futility blog syndicated Source Type: blogs
Oh So Quietly, Evidence of Bad Health Care Corporate Leadership Accumulates - Three AstraZeneca Settlements
While the news media is distracted by seemingly more spectacular issues, we hear the steady drip, drip, drip oflegal cases suggesting just how systemically bad the leadership of big health care organizations is. From February 2015 to now, for example, there have been three cases involving multinational pharmaceutical giant AstraZeneca.Settlement of Allegations of Kickbacks to Give AZ Drugs Preferred Status in FormulariesFirst, in February 2015, reported in most detail by Ed Silvermanin the Wall Street Journal,AstraZeneca has agreed to pay the federal government $7.9 million to settle allegations the drug maker paid k...
Source: Health Care Renewal - September 8, 2016 Category: Health Management Tags: AstraZeneca bribery deception impunity kickbacks legal settlements Source Type: blogs
Health Affairs ’ September Issue: Payment Reforms, Prescription Drugs, And More
The September issue of Health Affairs, a variety issue, includes a number of studies examining aspects of payment reform, the impact of certain ACA provisions, the value of some high-cost anticancer drugs, and more. It also includes a DataGraphic examining aging and health.
DATAWATCH: New evidence of rapid physician practice consolidation, 2013–15
In the past few decades, group physician practices have become more of the norm, and the proportion of physicians in larger groups has grown. David Muhlestein and Nathan Smith, with Leavitt Partners in Salt Lake City, Utah, looked at Medicare’s Physician Compare data for the ...
Source: Health Affairs Blog - September 7, 2016 Category: Health Management Authors: Lucy Larner Tags: Elsewhere@ Health Affairs Featured Health Affairs journal Source Type: blogs
